Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

January 8, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805310/0/en/Monte-Rosa-Therapeutics-Provides-Corporate-Update-and-Key-Anticipated-Milestones-for-2024.html

Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024

Received US FDA Fast Track Designation for MRT-2359 for previously treated, metastatic small cell lung cancer with L- or N-MYC expression

Read more at globenewswire.com

Related news for (GLUE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.